In a nutshell
This study investigated the safety of the chemotherapies mFOLFOX6 and XELOX in Japanese colon cancer patients. Researchers suggested that the safety of both treatments is acceptable.
FOLFOX chemotherapy is the standard treatment for stage 3 colon cancer patients who underwent surgery. mFOLFOX6 combines leucovorin, fluorouracil and oxaliplatin and is associated with severe neuropathy (numbness of arms and/or legs) or allergic reactions in these patients.
Oxaliplatin plus capecitabine (XELOX) was shown to have an improved 3-year disease-free survival. This led to the approval of this therapy in Japan to treat stage 3 colon cancer patients.
There are no studies comparing the safety of both oxaliplatin-based treatments.
Methods & findings
The objective of this study was to investigate the effectiveness and safety of both mFOLFOX and XELOX therapies to treat Japanese stage 3 colon cancer patients who underwent surgery.
This study included 132 patients who underwent 12 cycles of mFOLFOX or 8 cycles of XELOX. 3-year disease-free survival (DFS; time from surgery to disease progression) and side effects were assessed.
All patients experienced side effects from treatment, of which 40% were moderate to severe. There was no significant difference in the rate of severe side effects between the treatments. The most common side effect was neuropathy in both treatments.
14 patients stopped treatment in the FOLFOX group and 8 in the XELOX group due to side effects.
The bottom line
This study concluded that both mFOLFOX6 and XELOX treatments have acceptable rates of side effects.
The fine print
Final conclusions in this study, with 3-year DFS determining the usefulness of these treatments, will be determined in 2019.
Published By :
International Journal of Colorectal Disease
Feb 27, 2018
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?